| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Shiga-like toxin II
ID: ALA2074580
Max Phase: Preclinical
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Alternative Forms
Associated Targets(non-human)
Abcb1a P-glycoprotein 3 (492 Activities)
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
References
| 1. Zhao YL, Du J, Kanazawa H, Cen XB, Takagi K, Kitaichi K, Tatsumi Y, Takagi K, Ohta M, Hasegawa T.. (2002) Shiga-like toxin II modifies brain distribution of a P-glycoprotein substrate, doxorubicin, and P-glycoprotein expression in mice., 956 (1): [PMID:12445692] [10.1016/s0006-8993(02)03546-1] |
Source
Source(1):